Population Health Innovations and Clinical Research

ARA1 · Evidence review for team discussion · 27 October 2026

What is supported

Medical technologies are present; population-health and clinical-research results require their own evidence.

Health employment and registered clinical participation establish an operating setting. Rural reach and local trial delivery still need site evidence. Retained industry context and the patent observations describe different populations.

Scope and boundary check

The unchanged screen finds 504 narrow and 695 broad current-CPC candidates, versus 468 and 682 at issue. These are overlapping screening counts among utility grants with Arkansas inventors dated 2015–2025, not validated area totals or uncertainty intervals.

Primary-document examples

• US10206651B2: Ultrasound/Doppler processing selects a measurement region and gate to calculate cardiac output. A health-measurement technology example; it does not establish population-health outcomes, a clinical trial or a ready care-delivery team.
• US10004538B2: A pivoting, locking surgical instrument manipulates spinal constructs. General medical-device activity is broader than the proposed rural referral or clinical-research application.
• US8991400B2: A shaped curable support is positioned beneath a patient's spine for emergency transport. Shows an emergency-care device subject, without evidence about service access, patient outcomes or deployment.

Decision to take next

Choose a provider-defined service or clinical question and verify its cohort, team and permitted data.

Confidence and remaining checks

Source identities, event dates, input hashes and the reviewed technical passages are checked. Area-wide membership remains provisional. Patent ownership, current team readiness, facility/data access, partner demand and commercial outcomes require separate evidence. Low patent counts do not disqualify an area.

Review method: abstract and first independent claim for three purposefully/hash-selected documents per area. This is a bounded analytical review, not a statistical accuracy estimate, external expert sign-off or legal opinion. The seven growth areas and proposed commitments remain in place.